Routine employment agreement renewal with no departure, guidance, or financial data, no actionable trading signal. Monitor next 10-Q for any pipeline updates or cash runway changes.
How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Aug 19 $1.38entry
- T+1 · 3mo ago −0.72%α +0.12% · $1.37
- T+5 · 3mo ago +7.25%α +7.63% · $1.48
- T+20 · 2mo ago +150.00%α +151.95% · $3.45
- T+60 · 5d ago +1.45%α +3.00% · $1.40
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
MediciNova entered into new executive employment agreements with CEO Yuichi Iwaki and CMO Kazuko Matsuda, formalizing base salaries ($690,246 for Iwaki, $540,143 for Matsuda), target bonuses, and severance terms including change-in-control protections. This is a routine compensation and retention filing with no departure, resignation, or financial results, it does not signal any operational or strategic change.
Key Facts
- CEO Yuichi Iwaki's annual base salary set at $690,246 with target bonus of 55% of base salary
- CMO Kazuko Matsuda's annual base salary set at $540,143 with target bonus of 40% of base salary
- Both executives receive 12-month salary severance on involuntary termination without cause (no change in control)
- On change-in-control termination: Iwaki gets 24 months salary + 24 months target bonus; Matsuda gets 18 months salary + 18 months target bonus
- Both executives get 100% accelerated equity vesting on change-in-control termination
- Agreements supersede prior employment and severance arrangements; no departures or resignations reported
Financial Impact
No material financial impact disclosed; incremental severance obligations are standard for a $66M market cap biotech
Risk Factors
- No financial or operational data in filing, limited read-through for equity value
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-356146 |
| Document: 0001193125-26-356146-index-headers.html | 0001193125-26-356146 |
| Document: 0001193125-26-356146-index.html | 0001193125-26-356146 |
| Document: 0001193125-26-356146.txt | 0001193125-26-356146 |
Track record
6 reports on MNOV
The track record builds as more bullish or bearish reports settle.
Filters
- Nov 16, 2026today 8-K Bearish 5/10 Entry $1.35 Now $1.34 +0.74% settles Dec 16
- Oct 30, 202617d ago SC 13G Neutral 3/10 Entry $1.44 Now $1.34 −6.94% settles Dec 1
- Sep 28, 20267w ago Press Release Mixed 5/10 Entry $2.10 to $1.40 Now $1.34 −36.19% ▼ −33.33% −33.30% vs SPY
- Sep 24, 20267w ago Press Release Mixed 7/10 Entry $2.65 to $1.41 Now $1.34 −49.43% ▼ −46.79% −46.37% vs SPY
- Sep 2, 202610w ago 8-K Bullish 5/10 Entry $1.43 to $1.68 Now $1.34 −6.29% ▲ +17.48% +17.57% vs SPY
- Aug 19, 202612w ago 8-K Neutral 2/10 Viewing Entry $1.38 to $3.45 Now $1.34 −2.90% ▲ +150.00% +151.95% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers